News

Genoskin launches new skin offering, NativeSkin® access, that increases accessibility to animal testing alternatives NativeSkin, the only ex vivo human skin model sold online, will be available to purchase daily at a key price point, making it easier to order even for larger volume sales Toulouse, France & Salem, MA, USA, September 1, 2020 - Genoskin, a biotechnology company developing ready-to-use human skinRead more

Genoskin’s CEO invited to talk at Empowered Patient Podcast A window into the latest innovations in health Empowered Patient Podcast started in 2014 to provide its audience with insights on “the latest innovations in digital health and the changing dynamic between doctors and patients.” The audience is composed of researchers, medical professionals, patient advocates, entrepreneurs, patients, caregivers, solution providers, students,Read more

(Virtually) Meet with Genoskin at BIO Digital 2020! From June 8 to 12, Genoskin will be participating in the brand new version of BIO International Convention, BIO Digital 2020. The new digital version of the BIO will welcome online more than 5,000 biotech and pharma professionals from over 55 countries. It's the most international edition to date! Thanks to theRead more

Genoskin selected for Round 2 of Mass Challenge Switzerland 2020! A few weeks ago, Genoskin entered the 2020 Mass Challenge Switzerland. We are now excited to announce that our company is moving on to Round 2 judging! Genoskin has been invited to participate in Round 2 judging of the Mass Challenge Switzerland on May 14th. Our Chief Commercial Officer, EricRead more

COVID-19 update: Genoskin R&D capabilities expanded As the COVID-19 outbreak continues to evolve, our priorities remain safety and contingency in supporting research and first responders. Globally, hospitals are now focused on life-saving efforts. All non-urgent surgeries have therefore been postponed to help hospitals deal with the increasingly high demand of ventilators. These new measures have impacted our sourcing network inRead more

Genoskin COVID-19 research preferred access program On Friday, March 13th 2020, Genoskin launched a preferred access program for all research teams actively developing therapeutic and vaccine technologies for the COVID-19 pandemic. The World Health Organization (WHO) officially declared on March 11th, the outbreak of COVID-19 a pandemic. The disease caused by SARS-CoV-2 has spread globally. Over 130,000 individuals are affected so

Read more